Hwang Euna, Song You Seong
Department of Plastic and Reconstructive Surgery, Bundang CHA Medical Center, CHA University, Seongnam, Korea.
J Craniofac Surg. 2017 May;28(3):838-841. doi: 10.1097/SCS.0000000000003411.
The hyaluronic acid-based filler (HA filler) is used worldwide in various applications. In particular, the HA filler is used in the plastics and cosmetic medical field for facial rejuvenation and contouring. In this setting, it is injected into the skin or underlying tissue. Complications of HA filler injection have been relieved using hyaluronidase. However, there is no standard dose to adjust for undesirable HA filler lumpness. In this study, the authors tried to analyze any quantitative correlation between HA filler and hyaluronidase. The back of each rat (total 14 rats) was divided into 4 sites. A volume of 0.5 mL HA filler was injected into the subdermal layer at each site and HA filler nodules were created on the dorsum of each rat. Each nodule was allocated to groups 1, 2, 3, and 4 according to the different concentrations of hyaluronidase. As a result, the injected HA filler volume doubled within 4 days of injection, and then decreased slowly thereafter in group 1 (control group with normal saline only). A 30 unit hyaluronidase treatment compensated for the initial volume increase (approximately 30%) with HA filler (0.5 ml) at the fourth day. Sixty units of hyaluronidase reduced the initial volume (0.5 mL) of overinjected or misplaced HA filler on the fourth day. Approximately 90 units of hyaluronidase can reduce to the volume by 0.25 mL (50%) of the injected HA filler on the fourth day. The authors believe that this quantitative analysis of hyaluronidase concentration is helpful to plan the amount of hyaluronidase for correction of HA filler injection errors.
基于透明质酸的填充剂（HA填充剂）在全球范围内有多种应用。特别是，HA填充剂用于整形和美容医学领域，以实现面部年轻化和轮廓塑形。在这种情况下，它被注射到皮肤或皮下组织中。透明质酸酶已被用于缓解HA填充剂注射的并发症。然而，对于不期望出现的HA填充剂结块，尚无标准剂量可用于调整。在本研究中，作者试图分析HA填充剂与透明质酸酶之间的任何定量相关性。将每只大鼠（共14只大鼠）的背部分为4个部位。在每个部位的皮下层注射0.5 mL的HA填充剂，在每只大鼠的背部形成HA填充剂结节。根据透明质酸酶的不同浓度，将每个结节分配到第1、2、3和4组。结果，在注射后4天内，第1组（仅用生理盐水的对照组）中注射的HA填充剂体积增加了一倍，此后缓慢下降。在第4天，30单位的透明质酸酶治疗可抵消HA填充剂（0.5 ml）最初的体积增加（约30%）。60单位的透明质酸酶在第4天可减少过量注射或位置不当的HA填充剂的初始体积（0.5 mL）。在第4天，约90单位的透明质酸酶可将注射的HA填充剂体积减少0.25 mL（50%）。作者认为，这种对透明质酸酶浓度的定量分析有助于规划用于纠正HA填充剂注射错误的透明质酸酶用量。
